Hepatitis C in HIV-positive patients--treatment and liver disease outcomes

Area of Science:

• Hepatology
• Infectious Diseases
• Immunology

Background:

• Hepatitis C virus (HCV) coinfection is prevalent in human immunodeficiency virus (HIV) positive individuals.
• HCV-related liver disease is a major cause of morbidity and mortality in coinfected patients, even with effective antiretroviral therapy.
• Current treatment guidelines recommend HCV treatment for coinfected patients when feasible.

Purpose of the Study:

• To review the current landscape of HCV treatment in HIV-coinfected patients.
• To discuss challenges and emerging strategies for managing liver disease in this population.
• To highlight the need for improved therapeutic options and earlier inclusion in clinical trials.

Main Methods:

• Review of current clinical guidelines and published literature on HIV/HCV coinfection.
• Analysis of treatment outcomes, including sustained virologic response (SVR) rates.
• Discussion of alternative management strategies for patients unable to receive standard HCV treatment.

Main Results:

• Sustained virologic responses (SVRs) to pegylated interferon-alpha and ribavirin are lower (27%-40%) in coinfected patients compared to HCV mono-infected patients.
• Maintenance interferon strategies are being explored to delay liver disease complications.
• For treatment-refractory or contraindicated patients, highly active antiretroviral therapy (HAART) with careful monitoring and lifestyle counseling may slow fibrosis progression.

Conclusions:

• Optimizing HCV treatment and management in HIV-coinfected individuals remains a critical challenge.
• Early referral for liver transplantation evaluation is crucial for coinfected patients with end-stage liver disease.
• Inclusion of coinfected patients in early-phase clinical trials for new direct-acting antiviral agents is essential for developing more effective therapies.